In the DESTINYBreast-04 study, T-DXd was compared to chemotherapy of the researcher’s choice in HER2-low advanced breast cancer, i.e., in cancers with immunohistochemical expression of HER2 1+ or 2+ with negative in situ hybridization. Here, ERBB2 is linked to cancer.